Patents by Inventor Juergen Karl Willmann

Juergen Karl Willmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AFFIBODY PROTEINS SPECIFIC FOR B7-H3 (CD276)
    Publication number: 20210340257
    Abstract: Affibody polypeptides that specifically bind to B7-H3 are provided. Exemplary anti-B7-H3 affibodies are provided. The affibody polypeptides specifically recognize and bind to B7-H3 with high affinity.
    Type: Application
    Filed: August 22, 2019
    Publication date: November 4, 2021
    Inventors: Lotfi Abou-Elkacem, Juergen Karl Willmann, Benjamin J. Hackel, Lawrence Arthur Stern, Patrick Samuel Lown, Amelie Margarete Marianne Lutz, Rakesh Kumar Bam
  • DETECTION OF PANCREATIC CANCER WITH AN ENGINEERED ANTI-THY1 SINGLE-CHAIN ANTIBODY
    Publication number: 20210054068
    Abstract: Compositions and methods for detection and diagnosis of pancreatic cancer are disclosed. An engineered anti-thymocyte differentiation antigen 1 (Thy1) single-chain antibody and bioconjugates thereof can be used for detecting and diagnosing pancreatic adenocarcinoma. The anti-Thy1 single-chain antibody selectively binds to the Thy1 antigen, which is overexpressed on pancreatic tumor neovasculature and precancerous lesions, and is capable of detecting pancreatic cancer even at the earliest stages of the disease. Thy1-targeted diagnostic agents can be produced by conjugation of the anti-Thy1 single-chain antibody to various diagnostic agents, such as contrast agents, photoactive agents, or detectable labels that are useful for detection and medical imaging of pancreatic tumors.
    Type: Application
    Filed: June 5, 2017
    Publication date: February 25, 2021
    Inventors: Lotfi Abou-Elkacem, Juergen Karl Willmann
  • Methods and compositions for cancer diagnosis
    Patent number: 10857244
    Abstract: The present invention provides reagents and methods for detecting cancer and precancerous lesions in a patient.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: December 8, 2020
    Assignees: University of Washington Through Its Center for Communication, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Teresa A. Brentnall, Juergen Karl Willmann, Sheng Pan
  • BREAST CANCER DETECTION USING B7-H3-TARGETED MOLECULAR IMAGING
    Publication number: 20200254118
    Abstract: Compositions and methods for detection and diagnosis of breast cancer are disclosed. In particular, the invention relates to the use of B7-H3-targeted imaging agents for molecular imaging of breast cancer. Vascular expression of B7-H3 is selectively and significantly higher in breast cancer tissues. Detection of B7-H3 can be used to distinguish between benign and malignant lesions with high diagnostic accuracy. B7-H3-targeted imaging agents can be produced by conjugation of a B7-H3-binding antibody, aptamer, or other ligand to various diagnostic agents, such as contrast agents, photoactive agents, or detectable labels that are useful for detection and medical imaging of breast cancer tumors.
    Type: Application
    Filed: December 2, 2016
    Publication date: August 13, 2020
    Inventors: Sunitha Bachawal, Juergen Karl Willmann
  • METHODS AND COMPOSITIONS FOR CANCER DIAGNOSIS
    Publication number: 20180289844
    Abstract: The present invention provides reagents and methods for detecting cancer and precancerous lesions in a patient.
    Type: Application
    Filed: April 12, 2018
    Publication date: October 11, 2018
    Inventors: Teresa A. Brentnall, Juergen Karl Willmann, Sheng Pan
  • Methods and Compositions for Cancer Diagnosis
    Publication number: 20150079003
    Abstract: The present invention provides reagents and methods for detecting cancer precancerous lesions in a patient.
    Type: Application
    Filed: May 1, 2013
    Publication date: March 19, 2015
    Inventors: Teri Brentnall, Juergen Karl Willmann, Sheng Pang